Neutrophil hyperexpression is recognized as a key prognostic factor for inflammation and is closely related to the emergence of a wide range of cardiovascular disorders. In recent years, S100 calcium binding protein A8/A9 (S100A8/A9) derived from neutrophils has attracted increasing attention as an important warning protein for cardiovascular disease. This article evaluates the utility of S100A8/A9 protein as a biomarker and therapeutic target for diagnosing cardiovascular diseases, considering its structural features, fundamental biological properties, and its multifaceted influence on cardiovascular conditions including atherosclerosis, myocardial infarction, myocardial ischemia/reperfusion injury, and heart failure.
Insomnia is a common sleep-wake rhythm disorder, which is closely associated with the occurrence of many serious diseases. Recent researches suggest that circadian rhythms play an important role in regulating sleep duration and sleep quality. Banxia Shumi decoction (BSXM) is a well-known Chinese formula used to treat insomnia in China. However, the overall molecular mechanism behind this therapeutic effect has not yet been fully elucidated. This study aimed to identify the molecular targets and mechanisms involved in the action of BSXM during the treatment of insomnia. Using network pharmacology and molecular docking methods, we investigated the molecular targets and underlying mechanisms of action of BSXM in insomnia therapy. We identified 8 active compounds from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and the traditional Chinese medicine integrative database that corresponded to 26 target genes involved in insomnia treatment. The compound-differentially expressed genes of the BXSM network indicated that cavidine and gondoic acid could potentially become key components of drugs used for insomnia treatment. Further analysis revealed that GSK3B, MAPK14, IGF1R, CCL5, and BCL2L11 were core targets significantly associated with the circadian clock. Pathway enrichment analysis of Kyoto Encyclopedia of Genes and Genomes revealed that epidermal growth factor receptor tyrosine kinase inhibitor resistance was the most prominently enriched pathway for BSXM in the insomnia treatment. The forkhead box O signaling pathway was also found to be significantly enriched. These targets were validated using the Gene Expression Omnibus dataset. Molecular docking studies were performed to confirm the binding of cavidine and gondoic acid to the identified core targets. To our knowledge, our study confirmed for the first time that the multi-component, multi-target, and multi-pathway characteristics of BXSM may be the potential mechanism for treating insomnia with respect to the circadian clock gene. The results of this study provided theoretical guidance for researchers to further explore its mechanism of action.
Background The Banxiaxiexin decoction constitutes a prevalent Traditional Chinese Medicine (TCM) formulation employed for the therapeutic intervention of vascular dementia. Despite its routine clinical application, the underlying molecular mechanisms that mediate its pharmacological efficacy remain elusive. To address this lacuna, the present study employed a multi-pronged analytical approach involving network pharmacology and molecular docking techniques. Methods Active phytochemical constituents and relevant pharmacological targets of Banxiaxiexin decoction were elucidated using data procured from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Targets germane to vascular dementia were aggregated from a comprehensive range of databases, including GeneCards, Online Mendelian Inheritance in Man (OMIM), Drugbank, Pharmacogenomics Knowledge Base (PharmGKB), and Therapeutic Target Database (TTD). A Protein-Protein Interaction (PPI) network was constructed to isolate core targets. Subsequent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were executed using METASCAPE. Tissue and organ-specific distribution of these targets were subsequently assessed. Molecular docking protocols were employed to evaluate the interactions between the identified potential targets and active constituents. Molecular dynamics simulations were conducted to further scrutinize the optimal core protein–compound complexes identified through molecular docking. Results A total of 133 active compounds and 64 putative targets of Banxiaxiexin decoction were identified. Topological analyses of the PPI network revealed a subset of 20 core targets. GO and KEGG pathway enrichment analyses substantiated that Banxiaxiexin decoction modulates genes implicated in pathways associated with oncogenesis, lipid metabolism and atherosclerosis, as well as Alzheimer's disease signaling pathways. Both molecular docking and molecular dynamics simulations affirmed a robust binding affinity between the active compounds and the isolated targets. Conclusions The present study adeptly elucidates the active components, prospective targets, and putative pathways implicated in the therapeutic efficacy of Banxiaxiexin decoction for vascular dementia. The data presented herein offer a novel methodological framework for the future investigation of the molecular mechanisms by which Banxiaxiexin decoction exerts its therapeutic effects. Furthermore, the delineated active constituents may serve as a propitious reservoir for subsequent drug development endeavors targeting vascular dementia.